DSIJ Mindshare

Tata Consultancy Services has launched the ADD (Advanced Drug Development) size feasibility platform which provides life sciences companies with a single, integrated platform that digitises the site selection and activation processes, and facilitates data-driven decision-making while assessing site feasibility for multi-site clinical trials.

Generally, D/E should be less than one as it lends financial stability. But there are capital intensive industries like infra, capital goods wherein D/E ratio remains at a higher level compared with the companies that operate in the FMCG and IT space which are like cash-generating machines.

Specialty pharmaceutical company, Unichem Laboratories informed the bourses that United States Food and Drug Administration (USFDA) has conducted a routine GMP surveillance at company’s Goa formulation facility. The company had submitted ANDAs from this facility.

India-based subsidiary of Dr. Reddy's, Aurigene has entered an exclusive collaboration agreement with the US-based oncology-focused biotech company Exelixis, Inc.

Overall volumes in futures & options currently stand at 2,27,94,937 contracts with a turnover of Rs. 15,25,426.99 crore.